Numinus Wellness Inc. (TSXV: NUMI) announced today that it has secured approval from Health Canada to conduct its feasibility study on MDMA-assisted therapy to treat post-traumatic stress disorder. The health department recently issued a “letter of no objection”, allowing the proposed study to proceed.
The single-arm, open-label safety and feasibility study is sponsored by the Multidisciplinary Association for Psychedelic Studies through its subsidiary MAPS Public Benefit Corporation.
In May 2021, MAPS reported the results from the Phase 3 clinical trial testing the efficacy and safety of MDMA-assisted therapy for PTSD. The results demonstrated that 88% of the participants that received the experimental sessions experienced clinically significant reduction in symptoms, with 67% no longer qualifying for a PTSD diagnosis compared to only 32% in the placebo group.
Following the federal regulatory approval, the company is gearing its study preparations to train staff, import medication, and obtain ethical approval related to COVID-19 protocols.
Beyond this study, the company is also undertaking further studies to assess the safety and psychoactive properties of the lab-produced extract from a Psilocybe mushroom product.
Numinus Wellness last traded at $1.14 on the TSX Venture.
Information for this briefing was found via Numinus Wellness. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.